Earnings Preview: Forest Labs - Analyst Blog
October 15 2012 - 11:15AM
Zacks
Forest Labs (FRX) will be announcing its second
quarter fiscal 2013 results on October 16. The Zacks Consensus
Estimate for the second quarter is 2 cents per share, representing
a year-over-year decline of 98%. The company is facing stiff
generic competition for its depression drug, Lexapro. According to
the Zacks Consensus Estimate, revenues are expected to fall 33.4%
to $779 million in second quarter of fiscal 2013.
First Quarter Fiscal 2013 Highlights
Forest Labs reported first quarter fiscal 2013 earnings per
share of 21 cents, well below the year-earlier earnings of $1.04
per share. Results were hit by the loss of exclusivity on Lexapro.
Excluding acquisition-related amortization costs, first quarter
fiscal 2013 earnings came in at $0.28. The Zacks Consensus Estimate
was $0.25 per share.
First quarter revenues declined 28.7% to $821 million, with net
sales dropped 31.9% to $751.8 million. Total revenues missed the
Zacks Consensus Estimate of $826 million.
Agreement of Estimate Revisions
Over the past 7 days, only 1 analyst raised their estimate for
second quarter 2013 earnings with no movement in the opposite
direction. However, over the last 30 days, there is a significant
negative bias in estimate revisions with 5 analysts cutting their
estimates. Only two analysts raised their estimates during this
time period.
Over the past 7 days, 3 of the 21 analysts providing estimates
have cut their fiscal 2013 estimates with no movement in the
opposite direction. Meanwhile, over the last 30 days, 5 of 21
analysts have cut their estimates for fiscal 2013 over the last 30
days with 2 analysts moving in the opposite direction.
Estimates for Forest Labs have been declining ever since the
company came out with updated guidance in June 2012. The company
slashed its outlook for fiscal 2013 mainly due to lower
expectations from Lexapro. Lexapro, which was a key revenue
generator at Forest Labs, lost exclusivity in March 2012. Forest
Labs, which had been previously expecting branded Lexapro sales of
$250 million, now expects sales of $215 million. The company said
that it had to cut its estimate due to the higher-than-expected
discounting in the market.
Another factor that is expected to affect sales is lower than
expected royalty income from Mylan (MYL) on sales
of its authorized generic version of Lexapro.
Magnitude of Revisions & Earnings
Surprise
With earnings estimate revisions showing a negative trend over
the last 30 days, second quarter fiscal 2013 estimates have gone
down by 2 cents. Meanwhile, fiscal 2013 estimates declined 3 cents
over the last 30 days. Fiscal 2013 estimates are down by a penny
over the last 7 days.
Forest Labs’ performance has been mixed over the last four
quarters. While the company surpassed expectations in the third and
fourth quarters of fiscal 2012, Forest Labs missed expectations in
the second quarter of fiscal 2012 and the first quarter of fiscal
2013. The average earnings surprise over the last four quarters is
a negative 2.56%.
Forest Labs is expected to deliver below expectations in the
third quarter of fiscal 2013. The company is expected to deliver a
negative earnings surprise of 150%.
Although Forest Labs had several regulatory wins in the past few
quarters, the ramp up of new products, especially Teflaro, has been
slow. We are also concerned that Forest Labs will keep spending at
high levels in support of new product launches.
Recommendation
We currently have a Neutral recommendation on Forest Labs, which
carries a Zacks #3 Rank (short-term Hold rating). We remain
concerned about long-term growth at Forest Labs, especially now
that Lexapro is facing stiff generic competition. While Forest Labs
has been working on getting new products approved, we don’t expect
new product sales will be enough to compensate for the loss of
Lexapro sales. Namenda will face generic competition in early 2015
- this puts another $1+ billion at risk.
Given the situation, we believe that Forest Labs will continue
to seek in-licensing and acquisition activities to grow its
pipeline. Forest Labs has made significant progress in this regard
and should be on the lookout for additional deals in the next
couple of years.
FOREST LABS A (FRX): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024